



GEDEON RICHTER

Divestiture of Richter's Romanian Wholesale and Retail Operations Completed

Budapest, Hungary – 15 May 2023 – Gedeon Richter Plc. ("Richter") hereby notifies its shareholders that the transaction announced on 21 October 2022 in respect of divestiture of Richter Group's Romanian wholesale and retail operations was approved by the Romanian competition authority on 9 May 2023. The deal was completed today by the transfer of shares of Pharmafarm S.A. and Gedeon Richter Farmacia S.A. companies.

About Richter

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China, in Latin America and in Australia. Having reached a market capitalization of EUR 3.9 billion (USD 4.1 billion) by the end of 2022, Richter's consolidated sales were approximately EUR 2.0 billion (USD 2.1 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.

For more information:

Investors:

Katalin Ördög +36 1 431 5680

Media:

Zsuzsa Beke +36 1 431 4888

Chemical Works of Gedeon Richter Plc.

Headquarters: H-1103 Budapest, Gyömrői út 19-21., Hungary • Postal address: H-1475 Budapest 10., Pf. 27, Hungary
Phone: +36 1 431 4000 • Fax: +36 1 260 6650, +36 1 260 4891 • Company Court of Budapest-Capital Tribunal Reg. No. Cg. 01-10-040944
EU Community VAT Identification No: HU 10484878 • Internet: www.gedeonrichter.com